Regeneron Pharmaceuticals Inc. (REGN)

408.81
1.80 0.45
NASDAQ : Health Technology
Prev Close 406.99
Open 407.79
Day Low/High 402.82 / 408.10
52 Wk Low/High 281.89 / 433.74
Volume 308.01K
Avg Volume 733.10K
Exchange NASDAQ
Shares Outstanding 107.37M
Market Cap 44.54B
EPS 22.60
P/E Ratio 19.15
Div & Yield N.A. (N.A)

Latest News

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

In this day and age, companies must be 'disruptors' or get left in the dust.

Teen Scientists Win $1.8 Million At Regeneron Science Talent Search 2019 With Innovative Ideas On Exoplanets, HIV And A Classic Math Problem

Teen Scientists Win $1.8 Million At Regeneron Science Talent Search 2019 With Innovative Ideas On Exoplanets, HIV And A Classic Math Problem

Top Award of $250,000 Goes to Ana Humphrey of Virginia in Nation's Oldest and Most Prestigious STEM Competition for High School Seniors

FDA Approves Dupixent® (dupilumab) For Moderate-to-severe Atopic Dermatitis In Adolescents

FDA Approves Dupixent® (dupilumab) For Moderate-to-severe Atopic Dermatitis In Adolescents

Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis

FDA Approves Dupixent® (dupilumab) For Moderate-to-severe Atopic Dermatitis In Adolescents

FDA Approves Dupixent® (dupilumab) For Moderate-to-severe Atopic Dermatitis In Adolescents

* Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis

Regeneron Announces Upcoming Investor Conference Call

Regeneron Announces Upcoming Investor Conference Call

TARRYTOWN, N.Y.

Teva Pharmaceuticals CEO Talks "Trough Year", 2020 Turnaround

Teva Pharmaceuticals CEO Talks "Trough Year", 2020 Turnaround

Teva's CEO explains why 2019 is a trough year for the Israeli pharma company.

Regeneron Announces Upcoming Investor Conference Presentation

Regeneron Announces Upcoming Investor Conference Presentation

TARRYTOWN, N.Y.

Sanofi And Regeneron Offer Praluent® (alirocumab) At A New Reduced U.S. List Price

Sanofi And Regeneron Offer Praluent® (alirocumab) At A New Reduced U.S. List Price

* This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients

Chart of the Day: Regeneron

Weekly Regeneron chart shows a strong breakout.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: JKS, KCAP, LAUR, REGN, WAT Downgrades: CVRR, IIIN Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative

Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative

So far 2019 is proving to be a year where things have a habit of working out right.

TheStreet Quant Rating: B (Buy)